Dr David Christmas, Dr Sean Hood & Prof David Nutt
Dr David Christmas MBChB MRCPsych, Clinical Lecturer in Psychopharmacology, University of Bristol.
Dr Christmas currently works in the academic Psychopharmacology Unit in Bristol. He has previously worked in the academic Psychopharmacology Unit in Perth, Australia. A main area of research interest is the neurobiology of mood and anxiety disorders amongst patients with medical illnesses. His current research includes the neurochemical changes induced by interferon treatment, especially changes in the brain serotonin system and how these relate to the development of mood disorders.
Dr Sean Hood MBBS MSc FRANZCP, senior lecturer in clinical psychopharmacology, School of Psychiatry & Clinical Neurosciences (M521), The University of Western Australia, Perth, Australia.
Dr Hood is psychiatrist in academic, public and private practice. He maintains a close working relationship with Prof Nutt's group in Bristol, UK. A main area of research interest is the neurobiology of anxiety and mood disorders. His recent research includes investigating neurotransmitter mechanisms in clinical anxiety disorders by pharmacological challenge.
Prof David Nutt, Head of the Department of Clinical Medicine and Dean of Clinical Medicine and Dentistry, based at the University of Bristol.
Prof Nutt received his undergraduate training in medicine at Cambridge and Guy's Hospital, and continued training in neurology to MRCP. After completing his psychiatric training in Oxford, he continued there as a lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then spent two years as Chief of the Section of Clinical Science in the National Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. On returning to England in 1988 he set up the Psychopharmacology Unit in Bristol, an interdisciplinary research grouping spanning the departments of Psychiatry and Pharmacology.
Prof Nutt is currently a member of the Advisory Council on the Misuse of Drugs, and Chair of its Technical Committee, as well as a member of the Committee on Safety of Medicines. In addition, he is advisor to the British National Formulary, the editor of the Journal of Psychopharmacology. He is President-elect of ECNP and the Past President of the British Association of Psychopharmacology.
Contributions to CNSforum by Dr David Christmas, Dr Sean Hood & Prof David Nutt:
30.06.2008
Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study
31.05.2008
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers
30.04.2008
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial
31.03.2008
Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder
29.02.2008
Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings
31.01.2008
Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia